Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab A/S and Incyte have entered a clinical trial collaboration to investigate a new treatment for KRAS G12D-mutated metastatic colorectal cancer. The Phase 1/2 study will assess Genmab's bispecific antibody, petosemtamab, in combination with Incyte's KRAS G12D inhibitor, INCB161734, and standard chemotherapy. Genmab will lead the study, while Incyte will supply the inhibitor and co-fund the trial, targeting a significant unmet medical need affecting about 40% of colorectal cancer patients.